<DOC>
	<DOCNO>NCT01048151</DOCNO>
	<brief_summary>While radiation therapy androgen ablation ( hormone reduction ) standard method treat locally advanced prostate cancer . New treatment combine radiation therapy effort improve cure rate . This study propose combine experimental drug , TNFerade™ Biologic , ( also call AdGVEGR.TNF.11D `` TNFerade '' ) different dose ( amount ) level combination radiation . TNFerade™ Biologic form gene transfer therapy inject tumor show increase effect radiation therapy .</brief_summary>
	<brief_title>TNFerade Biologic Treat Locally Advanced Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Inclusion Criteria Histological document highrisk localized prostate cancer define clinical stage &gt; =T3 Gleason score ≥8 . Lack distant metastasis ( include bone , liver , extrapelvic lymph node metastasis ) standard CT bone scanning . Patients suspect histologically confirm pelvic lymph node metastasis eligible . Normal organ function define : Hgb &gt; 10 mg/dl ( may transfuse erythropoietin ) ; Platelets &gt; 100,000/l ; Absolute neutrophil count &gt; 1500/l . Bilirubin &lt; 1.5 mg/dl . AST ALT &lt; 1.5X upper limit normal . Written sign informed consent . Exclusion Criteria Absolute relative contraindication prostate radiotherapy include limited prior pelvic radiotherapy , active infectious inflammatory colitis , inability lay supine daily radiation treatment . Requirement ongoing antithrombotic treatment coumadin one derivative , heparin one derivative , thrombin inhibitor . Low dose aspirin prevention cardiovascular event acceptable . Active vascular disease define stroke , transient ischemic attack ( TIA ) , myocardial infarction , vascular procedure perform ischemic disease within last 6 month . History thrombosis ( pulmonary embolism ( PE ) deep vein thrombosis ( DVT ) ) know thrombophilia . Coagulopathy ( INR &gt; 1.5 , PTT ratio &gt; 1.5 ) Major surgery within last 1 month ( excludes minor superficial surgery , biopsy , minimally invasive approach ) . Chemotherapy experimental medication within 4 week study entry . Chronic treatment great 6 month oral steroid dose 10 mg/day prednisolone ( equivalent ) . Clinical evidence active infection type . HIVpositive patient receive combination antiretroviral therapy . Other significant concurrent medical psychiatric illness would limit compliance study . Unwilling use condoms another barrier method birth control least 8 week follow last dose TNFerade™ Biologic form birth control least one year .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Prostate</keyword>
	<keyword>TNFerade Biologic</keyword>
</DOC>